INO-5401+INO-9012+LIBTAYOの新興薬剤に関する洞察と市場予測：2032年

Inovioががん治療薬として開発中のINO-5401は、T細胞活性化DNA免疫療法です。INO5401は、イノビオのヒトテロメラーゼ（hTERT）、ウィルムス腫瘍遺伝子-1（WT1）、PSMAなど複数のがんに広く見られるSynCon抗原を含む複数の抗原をコードしています。また、INO-9012は同社が開発したDNAベースのがんワクチンです。これはインターロイキン12（IL-12）をコードするDNA分子（プラスミド）で構成されています。インターロイキン12は、外敵の侵入に反応して様々な免疫細胞（マクロファージや樹状細胞など）から自然に産生される炎症分子です。現在、この治療薬は、多くの種類のがんやウイルス感染症を治療するために、他の実験的治療薬と組み合わせて研究されています。

INO-9012は、電気ショックを用いてDNAを細胞に導入するエレクトロポレーション法により、患者の筋肉に投与されます。投与されると、患者の細胞はDNAを読み取ってIL-12を産生し、このIL-12はT細胞と呼ばれる特殊な免疫細胞の増殖を促進することによって免疫系を活性化します。T細胞は次にインターフェロンγ（IFN-γ）と呼ばれるその他の細胞シグナル分子の産生を刺激し、腫瘍細胞やウイルス感染細胞に対してナチュラルキラー細胞（NK細胞）やキラーT細胞などの他のタイプの免疫細胞を活性化させ、その結果、増殖を抑制し、死滅させます。同社は年次報告書（2021年）の中で、新たに多形性膠芽腫（GBM）と診断された患者を対象としたINO-5401とINO-9012（IL-12プラスミド）の第I/II相免疫腫瘍学試験（リジェネロン・ファーマシューティカルズとサノフィが共同開発したセミピリマブとの併用試験）が終了したことに言及しています。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化することが予想されます。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、INO-5401+INO-9012+LIBTAYOの優位性に影響を与える可能性のある機会を模索しています。GBMを対象とした他の新興製品がINO-5401+INO-9012+LIBTAYOと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えることになります。

当レポートでは、主要7ヶ国におけるINO-5401+INO-9012+LIBTAYO市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するINO-5401+INO-9012+LIBTAYOの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 INO-5401+INO-9012+LIBTAYO市場評価

• GBMに対するINO-5401+INO-9012+LIBTAYOの市場見通し
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するINO-5401+INO-9012+LIBTAYOの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: INO-5401+ INO-9012 + LIBTAYO, Clinical Trial Description, 2023
• Table 2: INO-5401+ INO-9012 + LIBTAYO, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: INO-5401+ INO-9012 + LIBTAYO Market Size in the 7MM, in USD million (2019-2032)
• Table 6: INO-5401+ INO-9012 + LIBTAYO Market Size in the US, in USD million (2019-2032)
• Table 7: INO-5401+ INO-9012 + LIBTAYO Market Size in Germany, in USD million (2019-2032)
• Table 8: INO-5401+ INO-9012 + LIBTAYO Market Size in France, in USD million (2019-2032)
• Table 9: INO-5401+ INO-9012 + LIBTAYO Market Size in Italy, in USD million (2019-2032)
• Table 10: INO-5401+ INO-9012 + LIBTAYO Market Size in Spain, in USD million (2019-2032)
• Table 11: INO-5401+ INO-9012 + LIBTAYO Market Size in the UK, in USD million (2019-2032)
• Table 12: INO-5401+ INO-9012 + LIBTAYO Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: INO-5401+ INO-9012 + LIBTAYO Market Size in the 7MM, USD million (2019-2032)
• Figure 2: INO-5401+ INO-9012 + LIBTAYO Market Size in the United States, USD million (2019-2032)
• Figure 3: INO-5401+ INO-9012 + LIBTAYO Market Size in Germany, USD million (2019-2032)
• Figure 4: INO-5401+ INO-9012 + LIBTAYO Market Size in France, USD million (2019-2032)
• Figure 5: INO-5401+ INO-9012 + LIBTAYO Market Size in Italy, USD million (2019-2032)
• Figure 6: INO-5401+ INO-9012 + LIBTAYO Market Size in Spain, USD million (2019-2032)
• Figure 7: INO-5401+ INO-9012 + LIBTAYO Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: INO-5401+ INO-9012 + LIBTAYO Market Size in Japan, USD million (2019-2032)

“"INO-5401 + INO-9012 + LIBTAYO Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about INO-5401 + INO-9012 + LIBTAYO for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the INO-5401+ INO-9012 + LIBTAYO for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the INO-5401+ INO-9012 + LIBTAYO for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INO-5401+ INO-9012 + LIBTAYO market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

INO-5401, being developed by Inovio for cancer treatment, is T-cell activating DNA immunotherapy. INO 5401 encodes multiple antigens, including Inovio's SynCon antigens for human telomerase (hTERT), Wilms tumor gene-1 (WT1), and PSMA are prevalent in multiple cancers. Besides, INO-9012 is an investigational DNA-based cancer vaccine developed by the same company. It consists of a DNA molecule (plasmid) that encodes for interleukin-12 (IL-12), which is an inflammatory molecule naturally produced by various immune cells (such as macrophages and dendritic cells) in response to foreign invasion. Currently, the treatment is being studied in combination with other experimental therapies for treating many types of cancers and viral infections.

INO-9012 is administered into the patient's muscle by electroporation, which uses electric shocks to introduce DNA into cells. Upon administration, the patient's cells read the DNA to produce IL-12, which activates the immune system by promoting the growth of specialized immune cells called T cells. T cells then stimulate the production of another cell-signaling molecule called interferon-gamma (IFN-γ), activating other types of immune cells, such as natural killer cells (NK cells) and killer T cells, against tumor cells or virus-infected cells resulting in the inhibition of their growth and their killing. In its annual report 2021, the company mentioned the Phase I/II immuno-oncology trial of INO-5401 and INO-9012 (IL-12 plasmid) in participants with newly diagnosed glioblastoma multiforme (GBM), in combination with cemiplimab developed jointly by Regeneron Pharmaceuticals and Sanofi has been completed.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the INO-5401+ INO-9012 + LIBTAYO description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on INO-5401+ INO-9012 + LIBTAYO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INO-5401+ INO-9012 + LIBTAYO research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around INO-5401+ INO-9012 + LIBTAYO.
• The report contains forecasted sales of INO-5401+ INO-9012 + LIBTAYO for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for INO-5401+ INO-9012 + LIBTAYO in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INO-5401+ INO-9012 + LIBTAYO Analytical Perspective by DelveInsight

In-depth INO-5401+ INO-9012 + LIBTAYO Market Assessment

This report provides a detailed market assessment of INO-5401+ INO-9012 + LIBTAYO for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

INO-5401+ INO-9012 + LIBTAYO Clinical Assessment

The report provides the clinical trials information of INO-5401+ INO-9012 + LIBTAYO for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INO-5401+ INO-9012 + LIBTAYO dominance.
• Other emerging products for GBM are expected to give tough market competition to INO-5401+ INO-9012 + LIBTAYO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INO-5401+ INO-9012 + LIBTAYO in GBM.
• Our in-depth analysis of the forecasted sales data of INO-5401+ INO-9012 + LIBTAYO from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INO-5401+ INO-9012 + LIBTAYO in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of INO-5401+ INO-9012 + LIBTAYO?
• What is the clinical trial status of the study related to INO-5401+ INO-9012 + LIBTAYO in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INO-5401+ INO-9012 + LIBTAYO development?
• What are the key designations that have been granted to INO-5401+ INO-9012 + LIBTAYO for GBM?
• What is the forecasted market scenario of INO-5401+ INO-9012 + LIBTAYO for GBM?
• What are the forecasted sales of INO-5401+ INO-9012 + LIBTAYO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to INO-5401+ INO-9012 + LIBTAYO for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. INO-5401+ INO-9012 + LIBTAYO Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. INO-5401+ INO-9012 + LIBTAYO Market Assessment

• 5.1. Market Outlook of INO-5401+ INO-9012 + LIBTAYO in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of INO-5401+ INO-9012 + LIBTAYO in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of INO-5401+ INO-9012 + LIBTAYO in the United States for GBM
  • 5.3.2. Market Size of INO-5401+ INO-9012 + LIBTAYO in Germany for GBM
  • 5.3.3. Market Size of INO-5401+ INO-9012 + LIBTAYO in France for GBM
  • 5.3.4. Market Size of INO-5401+ INO-9012 + LIBTAYO in Italy for GBM
  • 5.3.5. Market Size of INO-5401+ INO-9012 + LIBTAYO in Spain for GBM
  • 5.3.6. Market Size of INO-5401+ INO-9012 + LIBTAYO in the United Kingdom for GBM
  • 5.3.7. Market Size of INO-5401+ INO-9012 + LIBTAYO in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options